UNSPSC 51201636: Lyme disease vaccine

This classification denotes vaccines for an infectious disease caused by a spirochete, borrelia burgdorferi, which is transmitted chiefly by Ixodes dammini and pacificus ticks in the United States and Ixodes ricinis in Europe. It is a disease with early and late cutaneous manifestations plus involvement of the nervous system, heart, eye, and joints in variable combinations. This disease was formerly known as Lyme arthritis and first discovered at Old Lyme, Connecticut.

UNSPSC 51201636 Lyme disease vaccine (Commodity) covers immunizations against Lyme disease and related tick-borne pathogens procured by state and local health agencies. The recent activity in the code shows limited direct alignment: the single posted opportunity involves Yellow Fever Vaccine rather than Lyme disease product, indicating either miscoding of the opportunity or sparse current demand for Lyme disease vaccines within state and local procurement channels. State health departments serve as the primary issuing bodies under this code, reflecting the public-health role in vaccine procurement and distribution.

The Mississippi State Department of Health posted a sole source notice on July 13, 2026 (objection deadline August 3, 2026) for Yellow Fever Vaccine from Sanofi Pasteur, Inc., though the notice does not disclose quantity, contract term, or estimated value. The mismatch between the Lyme disease vaccine code designation and the Yellow Fever Vaccine solicitation suggests either a data-entry error or that state procurement systems are applying broad immunization codes across disparate vaccine products. No other recent state or local opportunities under this code appear in the source. Firms pursuing vaccine supply contracts to state health departments should monitor for competitive solicitations once sole source designations are resolved or withdrawn, and should track whether Lyme disease vaccine demand emerges as a distinct procurement line in coming quarters.